Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
NASDAQ:ENTX
Price:
1.98 USD
-1%
Market Closed
Updated:
Apr 29, 2024
Entera Bio Ltd
Cash from Financing Activities
|
Entera Bio Ltd
Cash from Financing Activities Peer Comparison
Comparables:
CLGN
KMDA
B
BLRX
URGN
B
BONS
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Financing Activities
$6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash from Financing Activities
$1.1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Financing Activities
$22.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Cash from Financing Activities
$15.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Financing Activities
$116.9m
|
CAGR 3-Years
92%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash from Financing Activities
-₪1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Entera Bio Ltd's Cash from Financing Activities?
Cash from Financing Activities
6m
USD
6m
USD
Based on the financial report for Dec 31, 2023, Entera Bio Ltd's Cash from Financing Activities amounts to 6m USD.
What is Entera Bio Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-9%
-9%
Over the last year, the Cash from Financing Activities growth was 60 260%. The average annual Cash from Financing Activities growth rates for Entera Bio Ltd have been 14% over the past three years , -9% over the past five years .
You don't have any saved screeners yet
